Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...

Abbott has recalled the FreeStyle Libre Glucose Monitors due to the risk of extreme heat and fire. The FDA has identified the recall as Class 1, the most severe type of recall. Product models consist ...

This morning Abbott announced that its continuous glucose monitor the FreeStyle Libre 3 earned a CE mark, making it cleared for use for individuals with diabetes living in the European Union. This ...

Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Through the reader, diabetes ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration with continuous glucose monitoring (CGM ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has an early lead in painless diabetes ...

SAN FRANCISCO--(BUSINESS WIRE)--Today, Nutrino, (www.nutrino.co) announces the collaboration with the LibreLink 1, 2 application, designed for Abbott’s FreeStyle Libre Flash Glucose Monitoring system.

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely ...

Walmart will become the first U.S. retailer to sell Abbott Laboratories' over-the-counter continuous glucose monitor Lingo in ...

Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. The company recently announced the receipt of Health Canada license for ...

In October 2025, Abbott Laboratories reported third-quarter results showing US$11.37 billion in sales and reaffirmed its 2025 earnings guidance, narrowing expected full-year adjusted diluted EPS to ...